MEDIFAST (MED)
(Real Time Quote from BATS)
$38.48 USD
+0.95 (2.53%)
Updated Mar 28, 2024 01:12 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
MED 38.48 +0.95(2.53%)
Will MED be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for MED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MED
MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?
MED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innovations Aid Medifast (MED), Lower Customer Attraction Ails
Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y
Medifast (MED) Q4 Earnings and Revenues Surpass Estimates
Other News for MED
Medifast: Cheap Valuation, Uncertain Future
Medifast Enters Oversold Territory
68 Graham Value Stocks, 57 Fit To Buy In March
FSTA: Consumer Staples Sector Dashboard For March
Director Scott Schlackman Sells Shares of Medifast Inc (MED)